Learning Objectives
- Identify who/when to test for FGFR alterations and interpret results to inform biomarker-driven treatment planning.
- Describe treatment sequencing, including where FGFR-targeted therapy may fit for eligible patients.
- Outline practical monitoring and adverse event management for FGFR inhibitors and apply best practices to integrate care into routine clinic workflows.
Moderators
Speakers
This program has been made possible through unrestricted support from Johnson & Johnson.